LinKinVax, now operating under the name EnnoDC, focuses on advanced dendritic cell targeting technology, which is pivotal in their approach to developing innovative treatments for various diseases. This technology is particularly significant in the context of cancer therapies, as it allows for the precise targeting of dendritic cells to enhance the immune response against tumors. EnnoDC's pipeline includes first-in-class clinical and preclinical programs aimed at treating HPV-induced cancers and prostate cancer, as well as addressing infectious diseases. This strategic evolution reflects the company's commitment to expanding its research and development efforts beyond infectious diseases to encompass a broader range of therapeutic areas.

The company emphasizes its dedication to scientific innovation and collaboration, as evidenced by its partnerships and featured deals. EnnoDC's research and development initiatives are designed to leverage its unique technology platform to create effective treatment options that can significantly improve patient outcomes. By focusing on both clinical and preclinical stages of development, LinKinVax aims to bring groundbreaking therapies to market, showcasing its role as a leader in the biopharmaceutical industry.

France

We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

Infectious Diseases

Urogenital Diseases

LinKinVax

Human immunodeficiency virus

HIV CD40 Env GP140

Biologics

Vaccines

COVID-19

COVID-19 CD40.RBDv and COVID-19 CD40.Pan.CoV

Human Papillomavirus

HPV CD40HVac

HIV CD40.HIV5pep

Prevention of chlamydia

Anti-CD40 Chlamydia

Europe - West

Therapeutic

LinKinVax

Company Details